Telix Pharmaceuticals Limited ACN 616 620 369 55 Flemington Road North Melbourne Victoria, 3051 Australia ASX ANNOUNCEMENT Page 1 ASX Listing Rule 7.3.4 Waivers Granted in Connection with Telix’s Proposed Acquisition of ITM Melbourne (Australia) and Indianapolis, IN (U.S.) – September 22,...
Grant of waivers of Listing Rule 7.3.4
Filed with ASX · · 4 pages · English
Summary by 6ix AI
The waivers allow Telix to seek shareholder approval for issuing shares as part of the acquisition consideration beyond the usual three-month period after the extraordinary general meeting. The filing outlines the nature and effect of the waivers, as well as the reasons for seeking them, emphasizing the need for flexibility in the timing of share issuance.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Telix Pharmaceuticals Limited on 6ix
In the deck
Earlier from Telix Pharmaceuticals
- Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse
- Telix and ITM Join Forces to Create Radiopharma Powerhouse
- FDA Approves Telix's Brain Cancer Imaging Drug Pixclara
- Application for quotation of securities - TLX
- FDA Approves Telix Brain Cancer Imaging Drug Pixclara
Later from Telix Pharmaceuticals
- Appendix 3Y Change in Director Interest-D Gill
- Change in substantial holding
- FDA Fast Track for BiPASS Pre Biopsy Prostate Imaging
- Telix Granted FDA Fast Track Designation for BiPASS Pre-Biopsy Prostate Cancer Imaging
- Notification regarding unquoted securities - TLX
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals